Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

This case series describes 6 cases of interstitial lung disease among patients with multiple sclerosis receiving long-term treatment with ocrelizumab.

Corresponding Author: Krzysztof W. Selmaj, MD, PhD, Center of Neurology, 12 Tylna St, 90-324 Lodz, Poland (kselmaj@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.